Relief Therapeutics Holdings AG (RLFTF) is a Swiss Company that trades on the U.S. OTC Exchange in addition to its Swiss Stock Exchange Listing (RLF). Only a week ago, Relief Therapeutics was trading under .10 per share. It was the rediscovery of the properties of their drug RLF-100, a proprietary synthetic form of Vasoactive Intestinal Polypeptide (VIP) also known as aviptadil, which has led to the justifiable interest in the company.
In a previous article, I described my rationale for following potential Covid-19 therapeutics over potential vaccines, and the progression of the